[
    [
        {
            "time": "",
            "original_text": "和讯SGI公司|万泰生物SGI评分为85分！上半年净利润超7亿同比增长翻2倍，资本狂热追捧，曾连续斩获26个涨停",
            "features": {
                "keywords": [
                    "万泰生物",
                    "SGI评分",
                    "净利润",
                    "同比增长",
                    "资本追捧",
                    "涨停"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "和讯SGI公司|万泰生物SGI评分为85分！上半年净利润超7亿同比增长翻2倍，资本狂热追捧，曾连续斩获26个涨停",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 10,
                "Source_Recency": 9
            }
        }
    ]
]